Business Description
Organon & Co
NAICS : 325412
SIC : 2834
ISIN : US68622V1061
Share Class Description:
OGN: Ordinary SharesTotal Employee Number:
10,000Compare
Compare
Traded in other countries / regions
OGN.USA0A9W.UK7XP.Germany1OGN.ItalyOGN.Mexico Index Membership
Russell 1000Russell 3000S&P 500 IPO Date
2021-05-14Description
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 9.49 | |||||
Debt-to-EBITDA | 6.57 | |||||
Interest Coverage | 2.38 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.27 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.5 | |||||
3-Year EBITDA Growth Rate | -10.4 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -4.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 2.89 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.69 | |||||
9-Day RSI | 70.99 | |||||
14-Day RSI | 72.75 | |||||
3-1 Month Momentum % | 121.65 | |||||
6-1 Month Momentum % | 86.77 | |||||
12-1 Month Momentum % | 34.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.97 | |||||
Quick Ratio | 1.42 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 177.81 | |||||
Days Sales Outstanding | 84.57 | |||||
Days Payable | 127.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.59 | |||||
Dividend Payout Ratio | 0.02 | |||||
3-Year Dividend Growth Rate | -32.8 | |||||
Forward Dividend Yield % | 0.59 | |||||
5-Year Yield-on-Cost % | 0.59 | |||||
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 2.74 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.82 | |||||
Operating Margin % | 18.94 | |||||
Net Margin % | 3.99 | |||||
EBITDA Margin % | 21.18 | |||||
FCF Margin % | 9.48 | |||||
OCF Margin % | 13.79 | |||||
ROE % | 32.06 | |||||
ROA % | 1.86 | |||||
ROIC % | 5.37 | |||||
3-Year ROIIC % | -39.25 | |||||
ROC (Joel Greenblatt) % | 39.44 | |||||
ROCE % | 9.68 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.52 | |||||
Forward PE Ratio | 3.92 | |||||
PE Ratio without NRI | 4.03 | |||||
Price-to-Owner-Earnings | 13.78 | |||||
PS Ratio | 0.57 | |||||
PB Ratio | 3.92 | |||||
Price-to-Free-Cash-Flow | 6.04 | |||||
Price-to-Operating-Cash-Flow | 4.15 | |||||
EV-to-EBIT | 10.7 | |||||
EV-to-Forward-EBIT | 7.48 | |||||
EV-to-EBITDA | 8.43 | |||||
EV-to-Forward-EBITDA | 6.77 | |||||
EV-to-Revenue | 1.78 | |||||
EV-to-Forward-Revenue | 2.84 | |||||
EV-to-FCF | 18.83 | |||||
Price-to-GF-Value | 0.93 | |||||
Price-to-Projected-FCF | 0.36 | |||||
Earnings Yield (Greenblatt) % | 9.35 | |||||
FCF Yield % | 16.47 | |||||
Forward Rate of Return (Yacktman) % | 11.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:OGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Organon & Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6,163 | ||
| EPS (TTM) ($) | 0.93 | ||
| Beta | 2.6309 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 134.76 | ||
| 14-Day RSI | 72.75 | ||
| 14-Day ATR ($) | 0.089717 | ||
| 20-Day SMA ($) | 13.4155 | ||
| 12-1 Month Momentum % | 34.37 | ||
| 52-Week Range ($) | 5.69 - 13.555 | ||
| Shares Outstanding (Mil) | 262.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Organon & Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Organon & Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:30 | In 137 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 136 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 39 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 13.39 (-0.07%) | ||
| USD 0.020000 Cash Dividend | 2026-05-11 | 13.35 (-0.07%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 13.34 (+0.00%) | ||
| Annual report for 2025 | 2026-02-24 | 7.92 (-2.70%) | ||
| USD 0.020000 Cash Dividend | 2026-02-23 | 8.10 (+5.33%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-12 08:30 | 7.69 (-0.90%) |
Show
Entries
Organon & Co Frequently Asked Questions
What is Organon & Co(OGN)'s stock price today?
The current price of OGN is $13.50. The 52 week high of OGN is $13.56 and 52 week low is $5.69.
When is next earnings date of Organon & Co(OGN)?
The next earnings date of Organon & Co(OGN) is 2026-08-05 Est..
Does Organon & Co(OGN) pay dividends? If so, how much?
The Dividend Yield % of Organon & Co(OGN) is 0.59% (As of Today), Highest Dividend Payout Ratio of Organon & Co(OGN) was 0.27. The lowest was 0.02. And the median was 0.22. The Forward Dividend Yield % of Organon & Co(OGN) is 0.59%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:OGN
No articles.
Press Release
Articles on Organon & Co
No articles.
Headlines
See More- 1
Jun 23, 2026
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada
Seeking Alpha • 5:28am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers